Details for Patent: 9,820,985
✉ Email this page to a colleague
Which drugs does patent 9,820,985 protect, and when does it expire?
Patent 9,820,985 protects TALZENNA and is included in two NDAs.
This patent has fifty-four patent family members in thirty countries.
Summary for Patent: 9,820,985
| Title: | Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP) |
| Abstract: | A compound having the structure set forth in Formula (I) and Formula (II): ##STR00001## wherein the substituents Y, Z, A, B, R.sub.1, R.sub.2, R.sub.3, R.sub.4 and R.sub.5 are as defined herein. Provided herein are inhibitors of poly(ADP-ribose)polymerase activity. Also described herein are pharmaceutical compositions that include at least one compound described herein and the use of a compound or pharmaceutical composition described herein to treat diseases, disorders and conditions that are ameliorated by the inhibition of PARP activity. |
| Inventor(s): | Wang; Bing (San Jose, CA), Chu; Daniel (Santa Clara, CA) |
| Assignee: | Medivation Technologies LLC (New York, NY) |
| Application Number: | 14/632,825 |
|
Patent Claim Types: see list of patent claims | Use; |
Drugs Protected by US Patent 9,820,985
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pfizer | TALZENNA | talazoparib tosylate | CAPSULE;ORAL | 211651-005 | Jun 20, 2023 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | TREATMENT OF ADULT PATIENTS WITH DELETERIOUS OR SUSPECTED DELETERIOUS GERMLINE BREAST CANCER SUSCEPTIBILITY GENE (BRCA)-MUTATED (GBRCAM) HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER | ⤷ Sign Up | ||||
| Pfizer | TALZENNA | talazoparib tosylate | CAPSULE;ORAL | 217439-001 | Mar 7, 2024 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | TREATMENT OF ADULT PATIENTS WITH DELETERIOUS OR SUSPECTED DELETERIOUS GERMLINE BREAST CANCER SUSCEPTIBILITY GENE (BRCA)-MUTATED (GBRCAM) HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER | ⤷ Sign Up | ||||
| Pfizer | TALZENNA | talazoparib tosylate | CAPSULE;ORAL | 211651-001 | Oct 16, 2018 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | TREATMENT OF ADULT PATIENTS WITH DELETERIOUS OR SUSPECTED DELETERIOUS GERMLINE BREAST CANCER SUSCEPTIBILITY GENE (BRCA)-MUTATED (GBRCAM) HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER | ⤷ Sign Up | ||||
| Pfizer | TALZENNA | talazoparib tosylate | CAPSULE;ORAL | 217439-002 | Mar 7, 2024 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | TREATMENT OF ADULT PATIENTS WITH DELETERIOUS OR SUSPECTED DELETERIOUS GERMLINE BREAST CANCER SUSCEPTIBILITY GENE (BRCA)-MUTATED (GBRCAM) HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 (HER2)-NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 9,820,985
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 2767537 | ⤷ Sign Up | CA 2019 00055 | Denmark | ⤷ Sign Up |
| European Patent Office | 2767537 | ⤷ Sign Up | 301021 | Netherlands | ⤷ Sign Up |
| European Patent Office | 2767537 | ⤷ Sign Up | PA2019522 | Lithuania | ⤷ Sign Up |
| European Patent Office | 2767537 | ⤷ Sign Up | LUC00140 | Luxembourg | ⤷ Sign Up |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
